Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 6/20 | 0.74 |
| ▸ | LMNA | P02545 | 5/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.74 |
| ▸ | SHBG | P04278 | 3/20 | 0.74 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.74 |
| ▸ | MEN1 | O00255 | 2/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | TSHR | P16473 | 2/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.74 |
| ▸ | G6PD | P11413 | 2/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.74 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.74 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.74 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.74 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.74 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3115963 | 1.00 | GPBAR1 (0.74) | GPBAR1LMNACYP3A4SHBGSERPINA6 | |
| SCHEMBL19750432 | 1.00 | GPBAR1 (0.74) | GPBAR1LMNACYP3A4SHBGSERPINA6 | |
| SCHEMBL19253221 | 1.00 | GPBAR1 (0.74) | GPBAR1LMNACYP3A4SHBGSERPINA6 | |
| SCHEMBL5173849 | 1.00 | GPBAR1 (0.74) | GPBAR1LMNACYP3A4SHBGSERPINA6 | |
| SCHEMBL13302861 | 1.00 | GPBAR1 (0.74) | GPBAR1LMNACYP3A4SHBGSERPINA6 | |
| SCHEMBL3115971 | 1.00 | GPBAR1 (0.74) | GPBAR1LMNACYP3A4SHBGSERPINA6 | |
| SCHEMBL1864977 | 1.00 | GPBAR1 (0.74) | GPBAR1LMNACYP3A4SHBGSERPINA6 | |
| SCHEMBL10060830 | 1.00 | GPBAR1 (0.74) | GPBAR1LMNACYP3A4SHBGSERPINA6 | |
| Androsterone SCHEMBL23031469 | 0.85 | G6PD (1.00) | GPBAR1LMNACYP3A4SHBGSERPINA6 | |
| Androsterone SCHEMBL12811704 | 0.85 | G6PD (1.00) | GPBAR1LMNACYP3A4SHBGSERPINA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10322138-B2 | Treatment of depressive disorders | PHERIN PHARMACEUTICALS, INC. (US) | 2019-06-18 | — | — | US | disclosed |
| US-9783592-B2 | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2017-10-10 | — | — | US | disclosed |
| EP-2938346-B1 | USE OF PREGN-4-EN-20-YN-3-ONE FOR THE TREATMENT OF DEPRESSIVE DISORDERS | PHERIN PHARM INC (US) | 2017-04-05 | — | — | EP | disclosed |
| US-20150320871-A1 | Glucagon Superfamily Peptides Exhibiting Nuclear Hormone Receptor Activity | UNIV INDIANA RES & TECH CORP (US) | 2015-11-12 | — | — | US | disclosed |
| EP-2938346-A1 | USE OF PREGN-4-EN-20-YN-3-ONE FOR THE TREATMENT OF DEPRESSIVE DISORDERS | Pherin Pharmaceuticals, Inc. (US) | 2015-11-04 | — | — | EP | disclosed |
| US-20150152187-A1 | Anti-PSMA Antibodies Conjugated to Nuclear Receptor Ligand Polypeptides | AMBRX, INC. (US) | 2015-06-04 | — | — | US | disclosed |
| WO-2014105620-A1 | USE OF PREGN-4-EN-20-YN-3-ONE FOR THE TREATMENT OF DEPRESSIVE DISORDERS | PHERIN PHARMACEUTICALS, INC. (US) | 2014-07-03 | — | — | WO | disclosed |
| US-20140187524-A1 | Treatment of Depressive Disorders | PHERIN PHARMACEUTICALS, INC. (US) | 2014-07-03 | — | — | US | disclosed |
| EP-1392320-B1 | 17-METHYLENE-ANDROSTAN-3a-OL ANALOGS AS CRH INHIBITORS | PHERIN PHARM INC (US) | 2007-01-10 | — | — | EP | disclosed |
| EP-1392320-B1 | 17-METHYLENE-ANDROSTAN-3a-OL ANALOGS AS CRH INHIBITORS | PHERIN PHARM INC (US) | 2007-01-10 | — | — | EP | disclosed |
| EP-1392320-A1 | 17-METHYLENE-ANDROSTAN-3a-OL ANALOGS AS CRH INHIBITORS | Pherin Pharmaceuticals, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| EP-1392320-A1 | 17-METHYLENE-ANDROSTAN-3a-OL ANALOGS AS CRH INHIBITORS | Pherin Pharmaceuticals, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20030220309-A1 | 17-methylenandrostan-3alpha-ol analogs as CRH inhibitors | PHERIN PHARMACEUTICALS, INC. | 2003-11-27 | — | — | US | disclosed |
| US-20030220309-A1 | 17-methylenandrostan-3alpha-ol analogs as CRH inhibitors | PHERIN PHARMACEUTICALS, INC. | 2003-11-27 | — | — | US | disclosed |
| US-20030220309-A1 | 17-methylenandrostan-3alpha-ol analogs as CRH inhibitors | PHERIN PHARMACEUTICALS, INC. | 2003-11-27 | — | — | US | disclosed |
| US-20030045514-A1 | 17-Methyleneandrostan-3alpha-ol analogs as CRH inhibitors | JULIAN N. STERN, A PROFESSIONAL CORPORATION | 2003-03-06 | — | — | US | disclosed |
| US-20030045514-A1 | 17-Methyleneandrostan-3alpha-ol analogs as CRH inhibitors | JULIAN N. STERN, A PROFESSIONAL CORPORATION | 2003-03-06 | — | — | US | disclosed |
| US-20030045514-A1 | 17-Methyleneandrostan-3alpha-ol analogs as CRH inhibitors | JULIAN N. STERN, A PROFESSIONAL CORPORATION | 2003-03-06 | — | — | US | disclosed |
| WO-2002089814-A1 | 17-METHYLENE-ANDROSTAN-3α-OL ANALOGS AS CRH INHIBITORS | PHERIN PHARMACEUTICALS, INC. (US) | 2002-11-14 | — | — | WO | disclosed |
| WO-2002089814-A1 | 17-METHYLENE-ANDROSTAN-3α-OL ANALOGS AS CRH INHIBITORS | PHERIN PHARMACEUTICALS, INC. (US) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150320871-A1 | Glucagon Superfamily Peptides Exhibiting Nuclear Hormone Receptor Activity | GIPR, GLP1R, GCGR | GPBAR1 12/4885LMNA 3486/4885CYP3A4 3118/4885 |
| US-10322138-B2 | Treatment of depressive disorders | HSD3B1, HSD17B3, HSD3B2 | GPBAR1 1360/4885LMNA 2137/4885CYP3A4 291/4885 |
| US-20150152187-A1 | Anti-PSMA Antibodies Conjugated to Nuclear Receptor Ligand Polypeptides | AR, PSMA1, NR2E3 | GPBAR1 252/4885LMNA 1671/4885CYP3A4 4372/4885 |
| US-20030220309-A1 | 17-methylenandrostan-3alpha-ol analogs as CRH inhibitors | CRH, CRHR1, CRHR2 | GPBAR1 1057/4885LMNA 4606/4885CYP3A4 1627/4885 |
| US-20140187524-A1 | Treatment of Depressive Disorders | HSD3B1, HSD17B3, HSD3B2 | GPBAR1 1360/4885LMNA 2137/4885CYP3A4 291/4885 |
| US-20030045514-A1 | 17-Methyleneandrostan-3alpha-ol analogs as CRH inhibitors | CRH, CRHR1, CRHR2 | GPBAR1 798/4885LMNA 4118/4885CYP3A4 810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.